Document is current
Any future updates will be listed below
-
Authors
Muratore, Francesco
Warrington, Kenneth J. https://orcid.org/0000-0001-7708-2487
Dejaco, Christian https://orcid.org/0000-0002-0173-0668
Cid, Maria C. https://orcid.org/0000-0002-4730-0938
Hellmich, Bernhard https://orcid.org/0000-0002-8014-1801
Morgan, Ann W. https://orcid.org/0000-0003-1109-624X
Croci, Stefania
Salvarani, Carlo https://orcid.org/0000-0003-3708-3148
- License Information
-
More Information
Article History
Accepted: 17 April 2026
First Online: 20 May 2026
Competing interests
: F.M. has received consulting fees and/or speaker honoraria from AbbVie, Amgen, AstraZeneca, CSL Vifor and GSK, and has received royalties from UpToDate. K.J.W. has received clinical trial support from BMS and consulting fees from Amgen, AstraZeneca and Sanofi. C.D. has received consulting fees and/or speaker honoraria from AbbVie, Fresenius, Janssen, Novartis, Sanofi and Sparrow. M.C.C. has received consulting fees from AbbVie, Alexion, AstraZeneca, Boehringer-Ingelheim, CSL-Vifor, GSK, Novartis and Royalty Pharma, and royalties from UpToDate. B.H. has received honoraria for advisory services from AbbVie, Alexion, AstraZeneca, Boehringer, BMS, Chugai, CSL Vifor, GSK, Novartis, Sanofi and Visterra, and honoraria for lectures from AbbVie, AstraZeneca, Boehringer, GSK, Pfizer, Medac, Novartis and Vifor Fresenius Medical Care Renal Pharma. A.W.M. has received consultancy fees payable to her institution from AstraZeneca, CSL Vifor, Glaxo Smith Kline, Roche/Chugai and Sanofi/Regeneron, outside the submitted work, and research and educational funding from Kiniksa Pharmaceuticals and Roche/Chugai, outside the submitted work. S.C. declares no competing interests. C.S. has received consulting fees and/or speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer, CSL Vifor, GSK and Novartis, and royalties from UpToDate.
